L-Ent-oxPt (IV)

L-Ent-oxPt IV (L-EOP) is a Oxaliplatin (HY-17371) -based siderophore-platinum conjugate. L-Ent-oxPt IV exhibits selectivity towards Escherichia coli and antibacterial activity through DNA damage[1].

Product Specifications

Product Name Alternative

L-EOP

UNSPSC

12352005

Target

Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/l-ent-oxpt-iv.html

Solubility

10 mM in DMSO

Smiles

CC(O[Pt]1(OC2=O)(OC2=O)(OC(CCC3=CN(CCOCCOCCOCCNC(C4=CC(C(N[C@@H](CO5)C(OC[C@@H](C(OC[C@H](NC(C6=C(O)C(O)=CC=C6)=O)C5=O)=O)NC(C7=C(O)C(O)=CC=C7)=O)=O)=O)=C(O)C(O)=C4)=O)N=N3)=O)[NH2][C@@H]8CCCC[C@H]8[NH2]1)=O

Molecular Formula

C54H65N9O27Pt

Molecular Weight

1467.22

References & Citations

[1]Guo C, et al., Investigation of Siderophore-Platinum (IV) Conjugates Reveals Differing Antibacterial Activity and DNA Damage Depending on the Platinum Cargo. ACS Infect Dis. 2024 Mar 4.